Lupus nephritis secondary prevention: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. {{Lupus nephritis}} ==References== {{refli...")
 
 
(4 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
Please help WikiDoc by adding content here. It's easy!  Click  [[Help:How_to_Edit_a_Page|here]] to learn about editing.
{{Lupus nephritis}}
{{CMG}}; {{AE}}[[User:Okamal|Omer Kamal, M.D.]][mailto:okamal@bidmc.harvard.edu <nowiki>[2]</nowiki>]
 
==Overview==
Secondary prevention strategies following systemic lupus erythematosus include using [[aspirin]], [[ACE inhibitor|ACE inhibitors]], and [[statins]] to reduce [[Atherosclerotic disease|atherosclerotic diseases]], and using [[Cancer screening|cancer screenings]].
 
==Secondary Prevention==
Aims of secondary prevention measures for SLE include:<ref name="pmid22593636">{{cite journal |vauthors=Maidhof W, Hilas O |title=Lupus: an overview of the disease and management options |journal=P T |volume=37 |issue=4 |pages=240–9 |date=April 2012 |pmid=22593636 |pmc=3351863 |doi= |url=}}</ref><ref name="pmid10782816">{{cite journal |vauthors=Zangger P, Gladman DD, Urowitz MB, Bogoch ER |title=Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus |journal=J. Rheumatol. |volume=27 |issue=4 |pages=919–23 |year=2000 |pmid=10782816 |doi= |url=}}</ref>
* Preventing [[glucocorticoid]] usage and using the minimum dosage to prevent [[osteonecrosis]] and [[Osteoporosis|osteoprosis]] side effects
* Decreasing [[Atherosclerosis|atherosclerotic]] events in patients
** Low doses of [[aspirin]]
** [[ACE inhibitor|ACE inhibitors]]
** [[Statins]]
* For prevention and/or early diagnosis of [[malignancies]]:
** Regular age-related specific [[cancer screening]] recommended for the general population


{{Lupus nephritis}}
==References==
==References==
{{reflist|2}}
{{Reflist|2}}
 
{{WH}}
{{WH}}
{{WS}}
{{WS}}
 
[[Category: (name of the system)]]
[[Category:Disease]]
[[Category:Nephrology]]
[[Category:Autoimmune diseases]]
 
[[Category:Needs content]]

Latest revision as of 17:45, 20 July 2018

Lupus nephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lupus nephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lupus nephritis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lupus nephritis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lupus nephritis secondary prevention

CDC on Lupus nephritis secondary prevention

Lupus nephritis secondary prevention in the news

Blogs on Lupus nephritis secondary prevention

Directions to Hospitals Treating Lupus nephritis

Risk calculators and risk factors for Lupus nephritis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]

Overview

Secondary prevention strategies following systemic lupus erythematosus include using aspirin, ACE inhibitors, and statins to reduce atherosclerotic diseases, and using cancer screenings.

Secondary Prevention

Aims of secondary prevention measures for SLE include:[1][2]

References

  1. Maidhof W, Hilas O (April 2012). "Lupus: an overview of the disease and management options". P T. 37 (4): 240–9. PMC 3351863. PMID 22593636.
  2. Zangger P, Gladman DD, Urowitz MB, Bogoch ER (2000). "Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus". J. Rheumatol. 27 (4): 919–23. PMID 10782816.

Template:WH Template:WS